Department of Psychiatry, North-Western Tuscany Region NHS Local Health Unit, Versilia Zone, 55049 Viareggio, Italy.
Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), Pietrasanta, 55045 Lucca, Italy.
Int J Environ Res Public Health. 2019 Feb 3;16(3):447. doi: 10.3390/ijerph16030447.
Mental Disorders and Heroin Use Disorder (HUD) often co-occur and constitute correlated risk factors that the authors believe are best considered from a unitary perspective. In this article we review and discuss data collected by the V.P. Dole Research Group in Dual Disorder (V.P. Dole DD-RG) patients according to the following six discussion points: (1) Treatment of personality disorders during Methadone Maintenance Treatment (MMT); (2) Treatment of Mood Disorders during MMT; (3) Treatment of Anxiety Disorders during MMT; (4) Treatment of Psychotic Disorders during MMT; (5) Treatment of violence during MMT; (6) Treatment of Alcohol Use Disorder (AUD) during MMT. In treating Mood Disorder in HUD patients, we must bear in mind the interactions (potentiation and side effects) between psychopharmacology, used substances and agonist opioid medications; the use of psychiatric medications as an anti-craving drug, and the possible use of agonist and antagonist opioid medications in treating the other mental disorders. In treating chronic psychosis in HUD patients, we must consider the potentiation and side effects of antipsychotic drugs consequent on HUD treatment, worsening addiction hypophoria and inducing a more severe reward deficiency syndrome (RDS) in hypophoric patients. Violence and AUD during MMT can benefit from adequate dosages of methadone and co-medication with Sodium gamma-hydroxybutyrate (GHB). The experience of our V.P. Dole DD-RG suggests the following: (a) DD is the new paradigm in neuroscience in deepening our understanding of mental health; (b) To successfully treat DD patients a double competence is needed; (c) In managing DD patients priority must be given to Substance Use Disorder (SUD) treatment (stabilizing patients); (d) Antidepressant use is ancillary to SUD treatment; antipsychotic use must be restricted to acute phases; mood stabilizers must be preferred; any use of Benzodiazepines (BDZs) must be avoided.
精神障碍和海洛因使用障碍(HUD)常常同时发生,并构成相关的风险因素,作者认为最好从单一的角度来考虑。在本文中,我们根据以下六个讨论点回顾和讨论了 V.P. Dole 双重障碍(V.P. Dole DD-RG)研究小组在双重障碍患者中收集的数据:(1)美沙酮维持治疗(MMT)期间治疗人格障碍;(2)MMT 期间治疗心境障碍;(3)MMT 期间治疗焦虑障碍;(4)MMT 期间治疗精神病障碍;(5)MMT 期间治疗暴力行为;(6)MMT 期间治疗酒精使用障碍(AUD)。在治疗 HUD 患者的心境障碍时,我们必须牢记精神药理学、使用物质和阿片类激动剂药物之间的相互作用(增效和副作用);将精神药物用作抗渴求药物,以及在治疗其他精神障碍时可能使用阿片类激动剂和拮抗剂药物。在治疗 HUD 患者的慢性精神病时,我们必须考虑到抗精神病药物因 HUD 治疗而产生的增效和副作用,加重成瘾性抑郁,并在抑郁患者中引起更严重的奖励缺乏综合征(RDS)。在 MMT 期间的暴力和 AUD 可以受益于美沙酮的适当剂量和与 γ-羟基丁酸(GHB)的联合用药。我们的 V.P. Dole DD-RG 的经验表明:(a)DD 是神经科学的新范例,加深了我们对心理健康的理解;(b)要成功治疗 DD 患者,需要双重能力;(c)在管理 DD 患者时,必须优先考虑物质使用障碍(SUD)治疗(稳定患者);(d)抗抑郁药的使用是 SUD 治疗的辅助手段;抗精神病药的使用必须限制在急性阶段;情绪稳定剂必须优先使用;任何使用苯二氮䓬类药物(BDZs)都必须避免。